New study tracks odevixibat safety for moms and babies
NCT ID NCT06258902
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 3 times
Summary
This study follows up to 20 people of any age who took the drug odevixibat while pregnant or breastfeeding. Researchers will collect routine medical data to see if the drug is linked to birth defects, pregnancy complications, or harm to the baby. No extra tests or visits are required—only information already recorded by doctors is used.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program
RECRUITINGWilmington, North Carolina, 28401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antimalarials be safely used in early pregnancy? a massive registry seeks answers
- Texts and local mentors: a new way to empower teen girls on contraception?
- Mindfulness during pregnancy: a new way to boost mental health and baby bonding?
- Teaching Moms-to-Be about seafood safety: a new weapon against toxic exposures?
- Can we improve emergency C-Sections for the sickest mothers?
- Can DIY insulin algorithms match commercial systems for pregnant women with type 1 diabetes?